

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/004043

International filing date: 07 February 2005 (07.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/542,117  
Filing date: 05 February 2004 (05.02.2004)

Date of receipt at the International Bureau: 07 April 2005 (07.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1302357

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*March 31, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/542,117**

**FILING DATE: February 05, 2004**

**RELATED PCT APPLICATION NUMBER: PCT/US05/04043**



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

17607 U.S. PTO  
020504

PTO/SB/16 (01-04)  
Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EL 999509493 US

322782 U.S. PTO  
60/542117  
020504

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
J. Kenneth		Hooper		Phoenix, Arizona	
Additional inventors are being named on the _____ 1 _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
Rational Design and Engineering of Proteins and Peptides for Immunomodulation					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number:		39978			
OR					
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		Zip	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages 8		<input type="checkbox"/> CD(s), Number _____			
<input type="checkbox"/> Drawing(s) Number of Sheets _____		<input type="checkbox"/> Other (specify) _____			
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		FILING FEE Amount (\$)			
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 501234		\$80.00			
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME Joseph W. Mott

TELEPHONE 602 262-5866

Date 02/04/2004

REGISTRATION NO. 35,621

(if appropriate)

Docket Number:

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Pr visional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PROVISIONAL APPLICATION COVER SHEET  
Additional Page

17607 U.S. PTO  
020504

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any] )	Family or Surname	Residence (City and either State or Foreign Country)
Lokesh	Joshi	Tempe, Arizona
Laura L.	Eggink	Scottsdale, Arizona
Vidydhari	Edupuganti	Tempe, Arizona
Srilakshmi	Ganta	Scottsdale, Arizona
Valerie	Jacobs	Phoenix, Arizona
Giovanna	Ghirlanda	Scottsdale, Arizona

[Page 2 of 2]

Number 1 of 1

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

## **Rational Design and Engineering of Proteins and Peptides for Immunomodulation**

Lokesh Joshi<sup>1\*</sup>  
Laura L. Eggink<sup>2</sup>  
Vidyadhari Edupuganti<sup>3</sup>  
Srilakshmi Ganta<sup>3</sup>  
Valerie Jacobs<sup>2</sup>  
J. Kenneth Hooper<sup>2</sup>  
Giovanna Ghirlanda<sup>4</sup>

<sup>1</sup>Harrington Department Of Bioengineering and Arizona Biodesign Institute, <sup>2</sup>School of Life Sciences, <sup>3</sup>Department of Computer Sciences, <sup>4</sup>Department of Chemistry and Biochemistry and Arizona Biodesign Institute  
Arizona State University, Tempe AZ 85287

\*Corresponding author: Lokesh Joshi ([ljoshi@asu.edu](mailto:ljoshi@asu.edu)) 480-727-7367

Funding Sources: BREU, Arizona Biodesign Institute and The Wallace Foundation

## ABSTRACT

A novel class of protein mimics is described with the potential to variably modulate the monocyte derived phagocytic cells. These mimics are derived from a naturally occurring serum protein, Vitamin-D binding protein, or Gc-globulin, which after specific deglycosylation is able to activate macrophages, enabling them to remove cancer cells and other foreign particles including bacteria and viruses. The partially deglycosylated variant of Vitamin D binding protein is known as macrophage activating factor (Gc-MAF). We have developed reduced-size polypeptide mimics of Gc-MAF protein. The active site domain of Gc-MAF was altered and optimized using commercially available molecular modeling software. The active amino acid residues were excised and implanted/grafted on a distinct protein scaffold. A peptide mimetic of the sugar residue, N-acetyl-D-galactosamine (GalNAc), which is required for activity, was achieved by screening with a GalNAc-specific lectin. The goal of this work is to develop novel, more stable and effective mimics of Gc-MAF monocyte mediated immunomodulation. The Gc-MAF mimics (from hereon called immunostimulatory peptides, IMPs) are made by chemical synthesis and/or recombinant techniques in living cells and/or cell-free environment. The IMPs were designed with/without amino acid side chain modifications (e.g., post-translational modifications) and are able to activate phagocytosis in a dose dependent manner by the monocyte-derived phagocytic cells. These IMPs can be administered to animal and human subjects to modulate the immune cell activation primarily to combat cancer and infectious diseases.

### *A. Cancer and Immune System:*

The immune system represents the endogenous defense mechanism that constantly scans for 'self' and 'non-self' molecules and organisms in the body. The immune response against 'non-self' entities is initiated upon their encounter with the phagocytic cells, such as macrophages and dendritic cells. The phagocytic cells engulf and digest the foreign substance/cells and display specific antigens on their surface. These antigenic fragments alert the helper T cells to begin a precisely choreographed attack which ultimately results in cellular and humoral immunity against the foreign intruder.

The immune system also recognizes cancer cells as foreign and removes them. However, the fact that this event is rare suggests that either the immune system does not easily distinguish cancer cells from healthy cells and/or cancer suppresses the immune system. Several approaches have been used to stimulate, repair or enhance the immune system, such as specific antibody targeting, lymphokine treatment and infusion of activated dendritic cells<sup>1</sup>. The induction of tumor immunity can be initiated by the effectors of innate immunity and further developed by cells of adaptive immunity, with phagocytic cells such as macrophages and dendritic cells playing a central role in linking these defense mechanisms.

### *B. Macrophage Activating Factor (MAF):*

Biological response modifiers such as immune stimulators, lymphokines, antibodies and specific carbohydrate epitopes activate the immune system to recognize cancer cells. Macrophage activating factors activate macrophages and allow them to act

as cytotoxic cells that non-specifically kill tumor cells. MAF is more or less an operational definition for a particular biological activity rather than the name of a distinct factor. One of the macrophage activating factors is derived from vitamin-D binding protein (VDBP), also known as Gc-globulin, and is called Gc-MAF. Gc-MAF is an abundant serum glycoprotein composed of three domains. The C terminal domain III contains 120 amino acids and is crucial for macrophage activation. Domain III of precursor Gc-MAF (VDBP) is post-translationally O-glycosylated at threonine 420 with an oligosaccharide moiety composed primarily of N-acetyl-D-galactosamine (GalNAc), galactose and sialic acid residues<sup>2</sup>. Activation of Gc-MAF is accomplished by selective removal of sugars by galactosidase and sialidase present on B- and T-cells, respectively<sup>3</sup> (Fig. 1). A single GalNAc residue is retained, and mediates the interaction of activated Gc-MAF with a C-type lectin receptor on the macrophage surface<sup>4, 5</sup>. This interaction results in macrophage activation for phagocytosis and subsequent antigen presentation.




Figure 1. Schematic diagram showing the *in vivo* activation of MAF by selective deglycosylation by  $\beta$ -galactosidase and sialidase and its inactivation by N-acetyl galactosaminidase.

adjuvant to enhance and accelerate the development of the immune response and to generate a large amount of antigen-specific antibodies. More importantly, systematic and repeated application of activated Gc-MAF has been shown to be effective as a general therapy for cancer and viral diseases.




Fig. 2: Strategies for rational design and protein engineering

However, cancerous cells secrete an enzyme,  $\alpha$ -N-acetyl-D-galactosaminidase (GalNAcase) into the blood stream, which results in complete deglycosylation of serum Gc-MAF leading to immunosuppression<sup>6, 7</sup>. It has been shown that the administration of enzymatically activated Gc-MAF to mice will overcome the inactivation and result in macrophage activation. These observations show that Gc-MAF can be useful as an

Until recently, mammalian serum has been the only source of Gc-MAF restricting its applications to patients. Concerns regarding potential contamination with infectious agents preclude obtaining Gc-MAF from this source. In addition, the serum-derived Gc-MAF has a molecular mass of ca. 52 kDa and carries only one active site (Thr-GalNAc); thus a large amount of this protein is required for therapeutic effects. The requirement for glycosylation restricts production of the full-length or derivative proteins to other eukaryotic systems.

### C. Rational Protein Drug Design:

In recent years, rational protein design has proven to be a valuable tool for optimizing therapeutic proteins<sup>8, 9</sup>. This approach enables researchers to design and develop macromolecular drugs with specific physical and biological attributes. *Several engineered proteins obtained by rational design are currently on the market or have completed clinical trials, generating a revenue of approximately US\$ 30 billions in 2001.* Examples of engineered protein therapeutics are HumaLog® (Eli Lilly) and NovoLog® (Novo Nordisk), fast-acting versions of insulin; Ontak® (Seragen), a natural toxin reengineered to target cancer cells; Fuzeon® (Trimeris), an inhibitor of HIV fusion derived from the viral protein gp41. In these drugs, properties such as activity, stability, solubility, specificity, immunogenicity and pharmacokinetics have been successfully optimized (Fig. 2). Starting from the detailed knowledge of the protein structure, rational design<sup>10, 11</sup> involves computational simulations and evaluations of a library of *in silico* mutants that are ultimately prepared and screened for activity *in vitro* and *in vivo*. The computational simulation steps allow the narrowing of the choice of protein variants to a manageable number. In contrast, experimental methods to create library of mutants rely on the randomization of residues at selected positions and results in extremely large libraries, which can be challenging to screen experimentally. For example, if one randomly mutates 10 residues in a protein to each of the 20 possible amino acids, the size of the library will be  $20^{10}$ ! Rational design allows to pre-screen a large number of mutants *in silico* and to restrict the size of the experimental library to a few mutants. In a second step, the experimental data obtained on each mutant can be utilized for the design of second-generation optimized proteins. This last step is conceptually similar to traditional Quantitative Structure-Activity Relationships (QSAR) methods, but utilizes protein-specific computational methods<sup>12, 13</sup>.

The developing field of peptide mimetics has also extended to non-amino acid structures. It has been shown that peptide sugar mimetics can induce functional carbohydrate cross-reactive immune responses in pathogen and tumor models<sup>14</sup>. Random peptide libraries displayed on phage provide a starting material for a number of applications in protein chemistry, including identification of peptide mimics of non-peptide ligands<sup>15</sup>. With this approach, a mimetic of GalNAc has been identified.

### D. Structural Optimization and Synthesis of IMPs:




Fig 3. Crystal structure of MAF. Domain III is highlighted in blue

Domain III of Gc-MAF is the site of the specific glycosylation event that leads to its bioactivation. In broader terms, a domain of a protein is an independently folded unit that can be separated from the intact protein and retain a specific structure. Domains often serve as the smallest functional elements of a complex protein, in which two or more domains can be combined to obtain complex functions. For example, Gc-MAF contains a vitamin D-binding domain, an actin-binding domain, and the glycosylation site, Domain III, which is crucial for macrophage



activation<sup>16</sup>. The use of Domain III in lieu of full length-Gc-MAF in therapy would present several advantages: first, the size of the isolated Domain III, ca. 120 amino acids, would make it a more tractable drug; second, by dissecting the desired function one would avoid possible cross-reactivity and side effects. However, preliminary studies show that the activity of the isolated Domain III is significantly reduced in comparison to the full length-Gc-MAF activity<sup>7</sup>. A possible explanation is given by visual inspection of the crystal structure of Gc-MAF<sup>17, 18</sup>: Domain III is a distorted three-helix bundle, and makes significant hydrophobic and ionic contacts with the remaining Gc-MAF (Fig. 3). It is conceivable that the isolated Domain III would not be sufficiently stable under physiological conditions.

We are using a rational design approach to prepare optimized, miniaturized proteins as mimetics of Domain III. A similar approach was pioneered by J. Wells' group at Genentech in the design of Protein A analogs<sup>19, 20</sup>, and has recently been used to design analogs of tDNA-binding domains, apoptotic proteins<sup>23, 24</sup>, and of the CD4 receptor<sup>25, 26</sup>. Because of the distorted three-helix bundle topology of Domain III, we decided to use a stable peptide scaffold of similar but more regular topology as a starting point. The putative active site of Domain III, defined as the portion of the protein surrounding the glycosylation site, was grafted onto a stable three-helix bundle scaffold obtained from the Protein Data Bank<sup>27</sup> and the resulting model protein optimized as described in Preliminary Studies.

The choice of the scaffolds was guided by three considerations: first, the size is considerably smaller than Domain III, and well within the limits for solid-phase synthesis of peptides; second, the scaffold is well characterized in terms of its stability and biophysical properties; third, the scaffold is amenable to structural studies. This approach has the advantage of starting from a structured template with minimal sequence homology to the native protein, thus avoiding possible interferences with undesired functions of the native protein, or sensitivity to proteases, which would be an important consideration in the *in vivo* use of biomimetics. Incorporation of the peptide mimetic of GalNAc into the peptide sequence provides the required recognition site at no additional cost and creates a structure that cannot be inactivated by glycosylases.

#### E. Protocol for IMPs Optimization:

In order to design an optimized version of Domain III, we used computer graphics




Fig. 7: Comparison of Domain III (A), the scaffold 1LQ7 (B), superimposition of the loop of Domain III onto one of the loops of 1LQ7 (C), and superimposition onto both loops of 1LQ7 (D).

to identify the critical residues for activity. Specifically, the glycosylated threonine 420 is located in a solvent-exposed loop, and protrudes from the start of one of the helices; the sequence surrounding Thr 420 is likely recognized by glycosylation enzymes and by the specific receptor located on the

surface of the macrophages. Thus, we narrowed the putative active sequence to approximately 20 residues, which comprise the loop and the first turn of the  $\alpha$ -helix on each side. Using Insight II, a molecular modeling software package, we investigated the stability of the isolated 20 amino acid sequence by running energy minimization experiments. The results show that the minimized loop presents severe deviations from the three-dimensional structure assumed in the native protein. Clearly, the underlying three-helix structure of Domain III is critical to restrain the conformation of the loop to the biologically active form. Therefore, we ~~decided to transfer the active loop of Domain III in the native conformation onto a more stable three-helix bundle obtained from the Protein Data Bank.~~ The scaffold chosen, 1LQ7, was originally designed in Prof. P.L. Dutton's lab at the University of Pennsylvania, and has the additional advantage of being amenable to solid-state synthesis<sup>27</sup>.

We started by aligning the sequence of the 20 amino acid loop with that of the scaffold, using the position of the helical residues on each side of the loop as guide. We overlaid the aligned coordinates of the loop onto those of the template (Fig. 7), obtaining a remarkable superimposition of the two structures. The scaffold loop was then replaced with that of the Domain III; a few alternative fragment lengths were tested for the substitution. In order to increase the protein activity, both scaffold loops were replaced with Domain III amino acids to yield a bifunctional molecule. The 70 amino acid constructs retain the overall three-helix bundle topology of Domain III, in a more regular and stable version. Each version was optimized by energy minimization routines and evaluated to identify significant deviations from the native loop conformation. The model that showed the smallest deviations from the native conformation was selected and will be the starting point for protein optimization. The amino acid sequence of the 1LQ7 scaffold with reengineered Gc-MAF loops is GSRVKALEEK VKALEEKVKA **LPNATPTE**LA KKKWEELKKK IEEELG **NATPTE** VKKVEEEVKKL EEEIKKL (the active amino acids from the natural Gc-MAF molecule are shown in bold).

#### F. Construction of a GalNAc Mimetic

Combinatorial peptide libraries displayed on phage M13 provided approximately  $3 \times 10^9$  variants of a 12-amino acid sequence. Each of these sequences were present in about 55 copies. The total library was screened with a GalNAc-specific lectin to search for a peptide mimetic of the sugar. Phage particles that bound to the lectin were eluted with free GalNAc and the process was repeated several times. After DNA of phage that were selected by this procedure was sequenced, a consensus amino acid sequence emerged. Insertion of variations of this sequence should allow construction of a series of IMPs with which binding affinities and consequently activity can be manipulated to achieve optimal clinical results. [Commercialization of sequences discovered using Ph.D.<sup>TM</sup>, a trademark of New England Biolabs, Inc., may require a license from Dyax Corp.]

#### G. Additional Activities

- We are identifying the minimal active site of Gc-MAF by systematically altering the loop residues to achieve the desired biological activities.
- Glycosylation of the IMPs will be achieved by either incorporating glycosylated amino acids or by in-vitro glycosylation reactions.

- Both hydrolyzable and non-hydrolyzable linkage between the sugar residue and the amino acids are being designed.
- The IMPs will be PEGylated for longer circulatory half-life in-vivo.

#### LITERATURE CITED:

1. Timmerman, J. M. & Levy, R. (1999). Dendritic cell vaccines for cancer immunotherapy. *Annu Rev Med* 50, 507-29.
2. Viau, M., Constans, J., Debray, H. & Montreuil, J. (1983). Isolation and characterization of the O-glycan chain of the human vitamin-D binding protein. *Biochem Biophys Res Commun* 117, 324-31.
3. Yamamoto, N. & Kumashiro, R. (1993). Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. *J Immunol* 151, 2794-802.
4. Iida, S., Yamamoto, K. & Irimura, T. (1999). Interaction of human macrophage C-type lectin with O-linked N-acetylgalactosamine residues on mucin glycopeptides. *J Biol Chem* 274, 10697-705.
5. Iida, S., Takeuchi, H., Kato, K., Yamamoto, K. & Irimura, T. (2000). Order and maximum incorporation of N-acetyl-D-galactosamine into threonine residues of MUC2 core peptide with microsome fraction of human-colon-carcinoma LS174T cells. *Biochem J* 347, 535-42.
6. Koga, Y., Naraparaju, V. R. & Yamamoto, N. (1999). Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice. *Proc Soc Exp Biol Med* 220, 20-6.
7. Yamamoto, N. & Naraparaju, V. R. (1997). Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. *Cancer Res* 57, 2187-92.
8. Lazar, G. A., Marshall, S. A., Plecs, J. J., Mayo, S. L. & Desjarlais, J. R. (2003). Designing proteins for therapeutic applications. *Curr Opin Struct Biol* 13, 513-8.
9. Marshall, S. A., Lazar, G. A., Chirino, A. J. & Desjarlais, J. R. (2003). Rational design and engineering of therapeutic proteins. *Drug Discov Today* 8, 212-21.
10. Bryson, J. W., Betz, S. F., Lu, H. S., Suich, D. J., Zhou, H. X., O'Neil, K. T. & DeGrado, W. F. (1995). Protein design: a hierarchic approach. *Science* 270, 935-41.
11. DeGrado, W. F. & Sosnick, T. R. (1996). Protein minimization: downsizing through mutation. *Proc Natl Acad Sci USA* 93, 5680-1.
12. Kraft, P., Bajgrowicz, J. A., Denis, C. & Frater, G. (2000). Odds and trends: Recent developments in the chemistry of odorants. *Angewandte Chemie-International Edition* 39, 2981-3010.
13. Hofmann, R. & Kitson, D. (2002). Building a Common Feature Hypothesis for Arylpiperazine based 5-HT3 antagonists. *Catalyst 4.0, Accelrys brochure*.
14. Monvzavi-Karbassi, B., Cunto-Amenesty, G., Luo, P., & Kieber-Emmons, T. (2002) Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery. *Trends Biotechnol.* 20, 207-214.
15. Hoess, R., Brinkmann, U. Handel, T. & Pastan, I. (1993) Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. *Gene* 128,43-49.
16. White, P. & Cooke, N. (2000). The multifunctional properties and characteristics of vitamin D-binding protein. *Trends Endocrinol Metab* 11, 320-7.
17. Head, J. F., Swamy, N. & Ray, R. (2002). Crystal structure of the complex between actin and human vitamin D-binding protein at 2.5 Å resolution. *Biochemistry* 41, 9015-20.

18. Swamy, N., Xu, W., Paz, N., Hsieh, J. C., Haussler, M. R., Maalouf, G. J., Mohr, S. C. & Ray, R. (2000). Molecular modeling, affinity labeling, and site-directed mutagenesis define the key points of interaction between the ligand-binding domain of the vitamin D nuclear receptor and 1  $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>. *Biochemistry* 39, 12162-71.
19. Starovasnik, M. A., Braisted, A. C. & Wells, J. A. (1997). Structural mimicry of a native protein by a minimized binding domain. *Proc Natl Acad Sci U S A* 94, 10080-5.
20. Li, B., Tom, J. Y., Oare, D., Yen, R., Fairbrother, W. J., Wells, J. A. & Cunningham, B. C. (1995). Minimization of a polypeptide hormone. *Science* 270, 1657-60.
21. Montclare, J. K. & Schepartz, A. (2003). Miniature homeodomains: high specificity without an N-terminal arm. *J Am Chem Soc* 125, 3416-7.
22. Chin, J. W., Grotzfeld, R. M., Fabian, M. A. & Schepartz, A. (2001). Methodology for optimizing functional miniature proteins based on avian pancreatic polypeptide using phage display. *Bioorg Med Chem Lett* 11, 1501-5.
23. Chin, J. W. & Schepartz, A. (2001). Design and Evolution of a Miniature Bcl-2 Binding Protein. *Angew Chem Int Ed Engl* 40, 3806-3809.
24. Rutledge, S. E., Chin, J. W. & Schepartz, A. (2002). A view to a kill: ligands for Bcl-2 family proteins. *Curr Opin Chem Biol* 6, 479-85.
25. Martin, L. & Vita, C. (2000). Engineering novel bioactive mini-proteins from small size natural and de novo designed scaffolds. *Curr Protein Pept Sci* 1, 403-30.
26. Martin, L., Stricher, F., Misse, D., Sironi, F., Pugniere, M., Barthe, P., Prado-Gotor, R., Freulon, I., Magne, X., Roumestand, C., Menez, A., Lusso, P., Veas, F. & Vita, C. (2003). Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. *Nat Biotechnol* 21, 71-6.
27. Dai, Q. H., Tommos, C., Fuentes, E. J., Blomberg, M. R., Dutton, P. L. & Wand, A. J. (2002). Structure of a de novo designed protein model of radical enzymes. *J Am Chem Soc* 124, 10952-3.